Agilent Investing $725M to Expand Therapeutics Manufacturing Capacity

URL22644220
SourceManufacturing Net
Date Published01/09/2023
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Agilent Technologies
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2023
Capital investment ($):725
City reshored to:Frederick
State(s) reshored to:CO
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredtherapeutic nucleic acids
What domestic positive factors made reshoring more attractive?Lead time/Time to market, Skilled workforce availability/training
Find Reshoring Articles